Branded Generics Market Analysis 2023-2032: Market Size, Top Segments, Leading Region Forecast | Pfizer Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd

The Branded Generics Global Market Report 2023 by The Business Research Company, provides branded generics market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten-year historic period – 2010-2021, and a ten-year forecast period – 2023-2032.

Learn More On The Branded Generics Market:

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

According to The Business Research Company’s Branded Generics Global Market Report 2023, the global branded generics market size will grow from $304.16 billion in 2022 to $329.98 billion in 2023 at a compound annual growth rate (CAGR) of 8.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the branded generics is expected to grow to $464.58 billion in 2027 at a CAGR of 8.9%.

The increasing prevalence of chronic diseases will drive the growth rate of branded generics market. Chronic diseases are long-lasting sicknesses that often cannot be healed, however, they are curable and controllable. Chronic diseases are increasing due to the increasing use of tobacco products, poor nutrition, physical inactivity, excessive use of alcohol, and others. Customers across the globe are more inclined toward branded generics to treat chronic diseases as they purchase them at a lower cost than usual medications.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample_request?id=7186&type=smp

The branded generics market is segmented:

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-hypertensive, Lipid Lowering Drugs, Anti-depressants, Anti-psychotics, Anti-Epileptics, Other Drugs

2) By Route of Administration: Topical, Oral, Parenteral, Other Routes of Administration

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics and Anti-inflammatory, Other Applications

The strategic partnership is a key trend in the branded generics market. The companies operating in branded generics are entering into a partnership with relevant companies to leverage each other’s resources and expand into new markets. In December 2021, Biocon Ltd., an India-based fully integrated biopharmaceutical company that develops affordable biosimilars, generic formulations & complex APIs, entered into a partnership with Tabuk Pharmaceuticals. The partnership will open the door for Biocon’s entry into the MENA area, which will now include Jordan, Lebanon, Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, and Iraq. This will help create a robust worldwide portfolio of goods, either directly or through strategic alliances, to provide patients all over the world with access to inexpensive treatments. These medications’ marketing authority will be held by Tabuk Pharmaceuticals, which is also in charge of their registration, importation, and promotion in Saudi Arabia and other Middle Eastern nations. Tabuk Pharmaceuticals is a Saudi Arabia-based company that manufactures and markets branded and generic pharmaceutical products.

The branded generics market report table of contents includes: